• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cybin Inc.

    2/18/26 1:55:40 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HELP alert in real time by email
    6-K 1 cybin-mcrxform6xkxfebruary.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of February, 2026.
    Commission File Number: 001-40673


    Cybin Inc.
    (Exact Name of Registrant as Specified in Charter)

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F □ Form 40-F ⊠

    INCORPORATION BY REFERENCE
    Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-292294) of the Company, as amended or supplemented.




    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    CYBIN INC.
    (Registrant)
     
    Date:February 18, 2026By:
    /s/ Greg Cavers    
    Name:Greg Cavers
    Title:Chief Financial Officer





    EXHIBIT INDEX

    99.1
    Material Change Report dated February 18, 2026

    Get the next $HELP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HELP

    DatePrice TargetRatingAnalyst
    2/2/2026$22.00Buy
    Jefferies
    More analyst ratings

    $HELP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome

    2/26/26 12:07:00 PM ET
    $ANRO
    $AXSM
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

    In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

    2/24/26 7:45:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

    Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two weeksAntidepressant treatment effects observed within one week and sustained for up to three months Findings reinforce the therapeutic potential of short-acting serotonergic agonists and inform Helus Pharma's HLP004 development program, with Phase 2 topline data in generalized anxiety disorder ("GAD") expected in Q1 2026 This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short

    2/17/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Helus Pharma with a new price target

    Jefferies initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $22.00

    2/2/26 6:51:26 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    SEC Filings

    View All

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    2/24/26 5:17:07 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    2/18/26 1:55:40 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Cybin Inc.

    SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)

    2/17/26 6:20:47 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Leadership Updates

    Live Leadership Updates

    View All

    Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

    In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

    2/24/26 7:45:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

    - Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder ("GAD") expected in Q1 2026 - This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- HELUS PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today re

    2/13/26 7:31:19 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

    Former President of Shire PLC's ("Shire") Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system ("CNS") programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated

    2/10/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care